192 related articles for article (PubMed ID: 24686948)
1. Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Shimizu F; Tasaki A; Sano Y; Ju M; Nishihara H; Oishi M; Koga M; Kawai M; Kanda T
PLoS One; 2014; 9(3):e92872. PubMed ID: 24686948
[TBL] [Abstract][Full Text] [Related]
2. Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.
Nishihara H; Shimizu F; Sano Y; Takeshita Y; Maeda T; Abe M; Koga M; Kanda T
PLoS One; 2015; 10(3):e0121488. PubMed ID: 25774903
[TBL] [Abstract][Full Text] [Related]
3. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica.
Tasaki A; Shimizu F; Sano Y; Fujisawa M; Takahashi T; Haruki H; Abe M; Koga M; Kanda T
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):419-30. PubMed ID: 24259591
[TBL] [Abstract][Full Text] [Related]
4. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P
Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630
[TBL] [Abstract][Full Text] [Related]
5. Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Festoff BW; Li C; Woodhams B; Lynch S
J Neurol Sci; 2012 Dec; 323(1-2):61-5. PubMed ID: 22967748
[TBL] [Abstract][Full Text] [Related]
6. Blood-brain barrier destruction determines Fisher/Bickerstaff clinical phenotypes: an in vitro study.
Saito K; Shimizu F; Koga M; Sano Y; Tasaki A; Abe M; Haruki H; Maeda T; Suzuki S; Kusunoki S; Mizusawa H; Kanda T
J Neurol Neurosurg Psychiatry; 2013 Jul; 84(7):756-65. PubMed ID: 23584494
[TBL] [Abstract][Full Text] [Related]
7. Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis.
Nishihara H; Shimizu F; Kitagawa T; Yamanaka N; Akada J; Kuramitsu Y; Sano Y; Takeshita Y; Maeda T; Abe M; Koga M; Nakamura K; Kanda T
Mult Scler; 2017 Mar; 23(3):382-394. PubMed ID: 27339072
[TBL] [Abstract][Full Text] [Related]
8. Immuno-metabolic impact of the multiple sclerosis patients' sera on endothelial cells of the blood-brain barrier.
Sheikh MH; Henson SM; Loiola RA; Mercurio S; Colamatteo A; Maniscalco GT; De Rosa V; McArthur S; Solito E
J Neuroinflammation; 2020 May; 17(1):153. PubMed ID: 32386505
[TBL] [Abstract][Full Text] [Related]
9. Sera from neuromyelitis optica patients disrupt the blood-brain barrier.
Shimizu F; Sano Y; Takahashi T; Haruki H; Saito K; Koga M; Kanda T
J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):288-97. PubMed ID: 22100760
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis.
Blecharz KG; Haghikia A; Stasiolek M; Kruse N; Drenckhahn D; Gold R; Roewer N; Chan A; Förster CY
Mult Scler; 2010 Mar; 16(3):293-302. PubMed ID: 20203147
[TBL] [Abstract][Full Text] [Related]
11. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
[TBL] [Abstract][Full Text] [Related]
12. Assessment of serum inflammatory parameters in RRMS and SPMS patients.
Nowak-Kiczmer M; Niedziela N; Czuba ZP; Sowa P; Wierzbicki K; Lubczyński M; Adamczyk-Sowa M
Neurol Res; 2024 Jun; 46(6):495-504. PubMed ID: 38697017
[TBL] [Abstract][Full Text] [Related]
13. Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis.
Proia P; Schiera G; Salemi G; Ragonese P; Savettieri G; Di Liegro I
Int J Mol Med; 2009 Dec; 24(6):743-7. PubMed ID: 19885613
[TBL] [Abstract][Full Text] [Related]
14. The role of endogenous antiradical protective system in multiple sclerosis.
Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
[TBL] [Abstract][Full Text] [Related]
15. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
[TBL] [Abstract][Full Text] [Related]
17. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
[TBL] [Abstract][Full Text] [Related]
18. Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes.
Soon D; Tozer D; Altmann D; Tofts P; Miller D
Mult Scler; 2007 Aug; 13(7):884-94. PubMed ID: 17468443
[TBL] [Abstract][Full Text] [Related]
19. Sera from patients with multifocal motor neuropathy disrupt the blood-nerve barrier.
Shimizu F; Omoto M; Sano Y; Mastui N; Miyashiro A; Tasaki A; Maeda T; Koga M; Kaji R; Kanda T
J Neurol Neurosurg Psychiatry; 2014 May; 85(5):526-37. PubMed ID: 23926278
[TBL] [Abstract][Full Text] [Related]
20. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
